News articles about Ardelyx (NASDAQ:ARDX) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.5923235295422 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
Shares of Ardelyx (ARDX) traded down $0.47 during mid-day trading on Monday, reaching $5.68. 481,000 shares of the company’s stock traded hands, compared to its average volume of 282,086. The firm has a market cap of $269.25, a P/E ratio of -2.55 and a beta of 0.44. Ardelyx has a 52-week low of $4.05 and a 52-week high of $15.40.
ARDX has been the topic of a number of analyst reports. Zacks Investment Research downgraded shares of Ardelyx from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Citigroup increased their price target on shares of Ardelyx from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, November 29th. Ladenburg Thalmann Financial Services cut their price target on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, November 22nd. Wedbush reiterated an “outperform” rating and issued a $12.00 price target (down from $13.00) on shares of Ardelyx in a research report on Tuesday, November 28th. Finally, Cantor Fitzgerald set a $12.00 price target on shares of Ardelyx and gave the company a “buy” rating in a research report on Tuesday, November 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Ardelyx has an average rating of “Buy” and a consensus price target of $12.93.
WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/12/ardelyx-ardx-earns-daily-media-impact-score-of-0-16.html.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.